This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Want Better Returns? Don?t Ignore These 2 Finance Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Here's Why You Should Retain Welltower Stock in Your Portfolio
by Zacks Equity Research
WELL is well-poised to gain from an aging population and a rise in senior citizens' healthcare expenditures. However, high competition is a concern.
How to Find Strong Finance Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is it Wise to Retain Healthpeak Properties Stock in Your Portfolio?
by Zacks Equity Research
DOC is likely to gain from solid demand for lab assets and rising senior citizens' healthcare spending despite high competition and debt burden.
Ventas (VTR) Up 2.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Welltower (WELL) Up 0.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Welltower (WELL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Healthpeak Properties (DOC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Healthpeak Properties (DOC) stock based on the movements in the options market lately.
American Tower Stock Gains on Q4 AFFO Beat, Revenues Rise Y/Y
by Zacks Equity Research
AMT's Q4 results reflect a year-over-year rise in revenues, led by property and service operations segment revenues. Strong organic tenant billing growth aids results.
VICI Properties' Q4 AFFO Meets Estimates, Revenues Rise Y/Y
by Zacks Equity Research
VICI's Q4 AFFO per share meets estimates. While revenues rise year over year, high interest expenses hurt the results to some extent.
Ventas Q4 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises
by Zacks Equity Research
VTR's Q4 results reflect higher same-store cash NOI due to SHOP same-store average occupancy growth.
Welltower's Q4 FFO & Revenues Beat Estimates, Same Store NOI Rises
by Zacks Equity Research
WELL's Q4 FFO outshines estimates, driven by a rise in revenues. Same Store NOI improves year over year.
Healthpeak's Q4 FFO Beats Estimates, Same-Store NOI Rises
by Zacks Equity Research
DOC's Q4 FFO tops estimates. Results reflect a year-over-year rise in revenues and total merger-combined same-store cash (adjusted) NOI.
Healthpeak (DOC) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Healthpeak (DOC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Healthpeak (DOC) Tops Q4 FFO and Revenue Estimates
by Zacks Equity Research
Healthpeak (DOC) delivered FFO and revenue surprises of 2.22% and 0.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Healthpeak Properties This Earnings Season?
by Zacks Equity Research
DOC's Q4 earnings are likely to have benefited from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Should You Retain Healthpeak Properties Stock in Your Portfolio Now?
by Zacks Equity Research
DOC is set to gain from growing demand for lab assets and senior citizens' healthcare spending. High competition and debt burden are concerns.
Want Better Returns? Don?t Ignore These 2 Finance Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
HealthPeak Boosts Flexibility With $3B Revolving Credit Facility
by Zacks Equity Research
DOC's operating partnership amends and extends its $3 billion revolving credit facility.
Healthpeak Properties' Strong Performance Leads to '24 Guidance Raise
by Zacks Equity Research
DOC raises 2024 guidance as a result of the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.
What's in the Offing for American Healthcare This Earnings Season?
by Zacks Equity Research
While AHR's Q3 earnings are likely to have benefited from favorable SHOP operating trends and a well-diversified tenant base, high interest expenses raise concerns.
Tesla and Nike have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tesla and Nike are part of the Zacks Bull and Bear of the Day article.
Pebblebrook Gears Up to Report Q3 Earnings: Key Factors to Consider
by Zacks Equity Research
PEB's Q3 earnings are likely to have benefited from business group, transient and leisure travel demand. However, high-interest expenses raise concerns.
Buy, Sell or Hold Medical Properties? Key Tips Ahead of Q3 Earnings
by Rohit Vasant Fatarpekar
MPW's Q3 earnings are likely to have been hurt by exposure to troubled operators and high interest expenses.
Ventas' Q3 FFO Meet Estimates on Higher Same-Store NOI, View Raised
by Zacks Equity Research
VTR's Q3 results reflect a year-over-year rise in revenues. The total property same-store NOI improves on strong performance across the business segments.